Establishing a Primary Lung Cancer Model to Identify Mutant Subpopulations That Cause Resistance to Molecularly-targeted Cancer Therapies.

被引：0
|
作者：
Banda, M. [1 ]
McKim, K. L. [2 ]
Myers, M. B. [2 ]
Parsons, B. L. [2 ]
机构：
[1] Covance Labs Inc, Indianapolis, IN USA
[2] US FDA, NCTR, Div Genet & Mol Toxicol, Jefferson, AR USA
来源：
ENVIRONMENTAL AND MOLECULAR MUTAGENESIS | 2018年 / 59卷
关键词：
D O I：
暂无
中图分类号：
X [环境科学、安全科学];
学科分类号：
08 ; 0830 ;
摘要：
S46
引用
收藏
页码：49 / 49
页数：1
相关论文
共 50 条
  • [31] Oncogenic Pathways, Molecularly Targeted Therapies, and Highlighted Clinical Trials in Non-Small-Cell Lung Cancer (NSCLC)
    Reungwetwattana, Thanyanan
    Weroha, Saravut J.
    Molina, Julian R.
    CLINICAL LUNG CANCER, 2012, 13 (04) : 252 - 266
  • [32] Clinical trial risk reduction in non-small cell lung cancer though the use of biomarkers and receptor-targeted therapies.
    Falconi, Adam
    Lopes, Gilberto
    Parker, Jayson L.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [33] Treatment of KRAS-Mutant Non-Small Cell Lung Cancer The End of the Beginning for Targeted Therapies
    Kaufman, Jacob
    Stinchcombe, Thomas E.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 317 (18): : 1835 - 1837
  • [34] EGFR plus MET Targeted Therapies for Overcoming Treatment Resistance in EGFR-Mutant Non-Small Cell Lung Cancer: A Case Report
    Martinez-Hernandez, Maria F.
    Lara-Mejia, Luis
    Izquierdo-Tolosa, Carlos
    Cabrera-Miranda, Luis
    Arrieta, Oscar
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 (12)
  • [35] TWIST1 is a key mediator of HGF-MET-driven resistance to targeted therapies in EGFR mutant and MET-driven lung cancer
    Yochum, Zachary A.
    Chatterjee, Suman
    Huang, Eric H.
    Maurer, Deena M.
    Attar, Myriam A.
    Dacic, Sanja
    Stabile, Laura P.
    Burns, Timothy F.
    CANCER RESEARCH, 2018, 78 (13)
  • [36] Strategies for Overcoming Acquired Resistance to Epidermal Growth Factor Receptor-Targeted Therapies in Lung Cancer
    Oxnard, Geoffrey R.
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2012, 136 (10) : 1205 - 1209
  • [37] Identify driver mutants in lung cancer by supernatants of pleural effusion and monitor resistance to targeted therapy.
    Wang, Yuehong
    Wang, Tao
    Xiao, Shanshan
    Mao, Ruifang
    Lin, Rui
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [38] New systemic strategies for overcoming resistance to targeted therapies in non-small cell lung cancer
    Genova, Carlo
    Rijavec, Erika
    Biello, Federica
    Rossi, Giovanni
    Barletta, Giulia
    Dal Bello, Maria Giovanna
    Vanni, Irene
    Coco, Simona
    Alama, Angela
    Grossi, Francesco
    EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (01) : 19 - 33
  • [39] Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies
    Leto, Simonetta M.
    Trusolino, Livio
    JOURNAL OF MOLECULAR MEDICINE-JMM, 2014, 92 (07): : 709 - 722
  • [40] Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies
    Simonetta M. Leto
    Livio Trusolino
    Journal of Molecular Medicine, 2014, 92 : 709 - 722
12345